Century Therapeutics, Inc. (IPSC): Price and Financial Metrics
IPSC Price/Volume Stats
| Current price | $3.05 | 52-week high | $5.51 |
| Prev. close | $3.09 | 52-week low | $1.28 |
| Day low | $2.98 | Volume | 65,600 |
| Day high | $3.37 | Avg. volume | 202,244 |
| 50-day MA | $4.16 | Dividend yield | N/A |
| 200-day MA | $2.94 | Market Cap | 197.69M |
IPSC Stock Price Chart Interactive Chart >
Century Therapeutics, Inc. (IPSC) Company Bio
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Latest IPSC News From Around the Web
Below are the latest news stories about CENTURY THERAPEUTICS INC that investors may wish to consider to help them evaluate IPSC as an investment opportunity.
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due |
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus StudyCentury (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%. |
Century Therapeutics, Inc.'s (NASDAQ:IPSC) largest shareholders are public companies who were rewarded as market cap surged US$47m last weekKey Insights The considerable ownership by public companies in Century Therapeutics indicates that they collectively... |
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus– Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication – – Company plans to initiate the Phase 1 clinical trial in the first half of 2024; initial data expected by year-end 2024 – – CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch |
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus ErythematosusPHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial |
IPSC Price Returns
| 1-mo | -31.15% |
| 3-mo | -26.15% |
| 6-mo | 107.48% |
| 1-year | 0.66% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -8.13% |
| 2023 | -35.28% |
| 2022 | -67.65% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...